title: Phenotypic variation in patients heterozygous for familial defective apolipoprotein B (FDB) in three European countries.
abstract: A glutamine-for-arginine substitution at amino acid position 3500 of apolipoprotein B (apo B) causes synthesis of LDL with reduced binding affinity to the LDL receptor (LDLR). The associated clinical syndrome has been named familial defective apolipoprotein B- 100 (FDB). In 205 FDB patients from Germany (n = 73). The Netherlands (n = 87), and Denmark (n = 45), we tried to assess determinants of variation in lipid concentrations. Besides age, sex, and geographic origin, variation in the LDLR gene was the most powerful determinant of variation in total cholesterol and LDL cholesterol levels. Polymorphic variation in the LDLR gene (SfaNI, exon 2; Nco I, exon 18) was associated with total cholesterol (TC) and LDL cholesterol (LDL-C) variation in women (SfaNI: P = .04 and .03 for TC and LDL-C, respectively; Nco I; P = .003 and .006, respectively), whereas the Ava II (exon 13) and the Pvu II (intron 15) polymorphisms were not. Combined information from all three LDLR exon polymorphisms showed that subjects with at least one S + A + N + allele had 13% to 20% higher TC than non-S + A + N + subjects (P = .02 [TC, men]; P = .01 [LDL-C, men]; P = .005 [TC, women]; and P = .004 [LDL-C, women]) and, together with age and geographic origin, accounted for 20% (women) and 19% (men) of the variation in LDL-C. The expected association of the apo E genotypes (e3e2, e3e3, and e3e4) with cholesterol concentrations was seen in S + A + N + but not in non-S + A + N + subjects and in P-P- but not in P + P + or P + P- subjects. With regard to clinical expression, FDB patients had lower TC and LDL-C levels and a lower prevalence of cardiovascular disease than 101 Danish patients with familial hypercholesterolemia.
authors.affiliation: Department of Internal Medicine and Cardiology A, University Hospital of Aarhus, Denmark.
authors.forename: P S
authors.initials: PS
authors.lastname: Hansen
authors.forename: J C
authors.initials: JC
authors.lastname: Defesche
authors.forename: J J
authors.initials: JJ
authors.lastname: Kastelein
authors.forename: L U
authors.initials: LU
authors.lastname: Gerdes
authors.forename: L
authors.initials: L
authors.lastname: Fraza
authors.forename: C
authors.initials: C
authors.lastname: Gerdes
authors.forename: F
authors.initials: F
authors.lastname: Tato
authors.forename: H K
authors.initials: HK
authors.lastname: Jensen
authors.forename: L G
authors.initials: LG
authors.lastname: Jensen
authors.forename: I C
authors.initials: IC
authors.lastname: Klausen
authors.forename: O
authors.initials: O
authors.lastname: Faergeman
authors.forename: H
authors.initials: H
authors.lastname: Schuster
mesh_terms: D000328:Adult; D053299:Apolipoprotein B-100; D001055:Apolipoproteins B / Q000235:genetics*; D001057:Apolipoproteins E / Q000235:genetics; D003718:Denmark; D005260:Female; D005787:Gene Frequency; D005858:Germany; D006579:Heterozygote; D006801:Humans; D006937:Hypercholesterolemia / Q000097:blood / Q000235:genetics*; D008071:Lipoprotein Lipase / Q000235:genetics; D008297:Male; D009426:Netherlands; D010641:Phenotype; D017354:Point Mutation; D012150:Polymorphism, Restriction Fragment Length; D011973:Receptors, LDL / Q000235:genetics; D012737:Sex Factors; D014280:Triglycerides / Q000097:blood
chemical_list: D053299:Apolipoprotein B-100; D001055:Apolipoproteins B; D001057:Apolipoproteins E; D011973:Receptors, LDL; D014280:Triglycerides; D008071:Lipoprotein Lipase